Adjustment of Chemotherapy Duration in Follicular Lymphoma According to Minimal Residual Disease Status
Status:
Recruiting
Trial end date:
2025-08-01
Target enrollment:
Participant gender:
Summary
Follicular lymphoma (FL) is a chronic indolent malignancy, where treatment with 6 cycles of
bendamustine obinutuzumab (BO) is highly effective but at a cost of increased adverse events.
Tumor specific DNA can be traced in blood and bone marrow of follicular lymphoma patients
even after therapy, and when detected after lymphoma treatment it is referred to as minimal
residual disease (MRD).
MRD elimination after effective lymphoma treatment is a marker for deep response and
correlates with prolonged remission.
In this study we aim to omit chemotherapy after 4 cycles of treatment in patients achieving
MRD elimination after 3 months of therapy, as well as complete metabolic response on positron
emission computed tomography (PET-CT), hoping to preserve treatment effectiveness while
reducing adverse events.
Phase:
Phase 2
Details
Lead Sponsor:
Meir Medical Center
Collaborators:
Assuta Ashdod Hospital Rabin Medical Center Tel-Aviv Sourasky Medical Center Ziv Medical Center